scott galloway glp 1 The Real Downside of GLP-1 Drugs (And Why Scott's Still Bullish) GLP-1s are the most underhyped
Description
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
A decade from now, the most popular GLP-1 drugs might advertise weight loss as a secondary benefit
At the time this article was written, a Mounjaro prescription was listed at over $1,000 per month at most pharmacies, and insurance coverage for the drug can be hard to find, especially for those without diabetes
It has a stronger and longer-lasting action in the body, enabling a higher dosage to result in more weight reduction
Animal and human studies published in English language were included
